HRT Therapy – Delving Into The Finer Nuances – Part I

HRT and osteoporosis
HRT or Hormone Replacement is a great treatment option for averting osteoporotic fractures during the course of its use, though its benefits plummet subsequent to its stoppage. The usage of HRT as a curative agent for this purpose alone is not counseled for majority of women. Though, in women with higher likelihood of osteoporosis, its usage could be cautiously considered, especially if other remedial agents are inapt.

Raloxifene – a selective oestrogen receptor modulator or SERM that has been researched in the MORE or Multiple Outcomes of Raloxifene trial, has shown to lower the occurrence of vertebral fractures in women having osteoporosis. Though there is no current proof of safeguard against fractures in the hip or other locations.

HRT and associated breast cancer risk
Majority of the randomized trials and observational researches has pointed to the raised chances of breast cancer related to current HRT usage. Though, on HRT discontinuation the level of risk is analogous to women that have never undergone HRT treatment.

Women need to be cautiously advised in regards to this heightened risk that appears to have a direct relation to the length of treatment and not the dosage.

The proof from the congregate arm of the WHI trial indicates that oestrogen-progesterone combo preparations raise breast cancer risk more than when oestrogen is administered solely.

A rise in the mammographic density amongst women on HRT is observed to lower the sensitivity of screening mammography and the raise the chances of being called again for additional investigations. HRT is contraindicated among women that had a history of breast cancer.

HRT and vasomotor symptoms
Raloxifene usage during HRT has been related to lowering risk of breast cancer though it raises occurrence of vasomotor signs.

Tibolone has triple combo properties that are oestrogenic, progestogenic and androgenic in nature. It has been observed to be effectual in treating vasomotor symptoms.

However, contrary to former ideas, latest data derived from the Million Women Study have suggested that tibolone might also be related to the raised likelihood of breast cancer.

HRT and associated cardiac risks
HRT has been shown in randomized HERS (Heart and Estrogen/progestin Replacement) study trials not to offer either primary or secondary safeguard against ischaemic heart disease or stroke. There is a raised likelihood of stroke and early increased chances of developing myocardial infarction among HRT users. The total risk of these conditions is directly proportion to age. Women with clinical proof of ischaemic heart disease, cerebrovascular disease or peripheral arterial disease are contraindicated for HRT usage.

Latest study is surfacing on the advantageous effect of HRT on heart risk if begun early, for instance with ten years of menopause.

Popularity: 2% [?]